Investing.com - Oric Pharma (NASDAQ: ORIC) reported first quarter EPS of $-0.52, $0.04 better than the analyst estimate of $-0.56. Revenue for the quarter came in at $0.00 versus...
By Davit KirakosyanInvesting.com -- Here is your daily Pro Recap of the biggest analyst picks you may have missed on InvestingPro since yesterday.FedEx rises on Stifel upgrade to...
ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in improving patients' lives by Overcoming Resistance In Cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its clinical-stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. ORIC-114, is a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency towards exon 20 insertion mutations. ORIC-944 is an allosteric inhibitor of the polycomb repressive complex 2 (PRC2).
|Moving Averages||Sell||Neutral||Buy||Strong Buy||Sell|
|Technical Indicators||Strong Sell||Sell||Strong Buy||Strong Buy||Strong Sell|
|Summary||Strong Sell||Neutral||Strong Buy||Strong Buy||Strong Sell|